कंपनी का अवलोकन
Serina Therapeutics, Inc. is a biotechnology firm dedicated to the development of pharmaceutical therapies designed to treat neurological disorders and manage pain conditions. The company operates within the healthcare sector and specifically functions in the biotechnology industry, a space characterized by high research and development expenditures and long regulatory pathways to market approval. According to the available data, the enterprise possesses a market capitalization of $24.87M and reported annual revenue of $130,000, while the specific count of employees is not listed in the provided records. These valuation and revenue figures indicate that the company is a micro-cap entity with a very small revenue base relative to its market capitalization, suggesting it is in an early-stage development phase where capital allocation focuses heavily on advancing clinical candidates like SER 252 rather than generating substantial commercial sales.
वित्तीय स्वास्थ्य
The financial statements reveal a revenue figure of $130,000 for the trailing twelve months, contrasted by a net income loss of $-19,436,000 and an EBITDA of $-23,949,000, illustrating a significant negative gap between top-line generation and bottom-line profitability. This disparity highlights a cost structure dominated by substantial operating expenses, likely driven by research and development costs and clinical trial expenditures typical for preclinical stage biotechnology firms. The company generated free cash flow of $-11,285,875, indicating a continuous burn rate that consumes liquidity without the benefit of positive cash generation from operations. Analysis of the margins shows a gross margin of 0.0%, an operating margin of -18478.5%, and a profit margin of 0.0%, all of which reflect the early-stage nature of the business where revenue has not yet scaled to cover fixed and variable costs effectively. Regarding liquidity and leverage, the company holds $3.06M in cash against $3.32M in total debt, while a debt-to-equity ratio is not calculable due to the nature of the financial data provided. The current ratio stands at 1.71, which suggests the company maintains adequate short-term assets to cover its short-term liabilities, providing a degree of financial stability despite the net loss position. Return on equity is reported at -8159.2% and return on assets at -219.6%, metrics that indicate management is currently utilizing shareholder capital and assets to generate losses rather than returns, a common characteristic for biotech firms in preclinical development.
मूल्यांकन आकलन
Valuation metrics present a complex picture due to the lack of profitability, with the trailing twelve-month P/E ratio listed as N/A and a forward P/E of -1.92. The negative forward P/E implies that expected earnings are anticipated to remain negative in the near future, preventing a meaningful comparison based on traditional earnings multiples. The price-to-book ratio is stated as -4.37, which indicates a market valuation significantly below the book value, a scenario often seen in distressed or pre-revenue biotechnology companies. Alternative valuation measures include a price-to-sales ratio of 191.34 and an EV/EBITDA of -1.26, suggesting that the market is pricing the stock based on potential future asset value or pipeline potential rather than current financial performance. The stock's price range over the past year has fluctuated between a 52-week high of $7.92 and a 52-week low of $1.22, with the current trading price situated within this volatile band. The beta value is 0.10, which implies that the stock price exhibits very low volatility relative to the broader market, moving significantly less than the overall index.
Growth & Income
Growth metrics for the company are unavailable in the provided data, with revenue growth year-over-year and earnings growth year-over-year both listed as N/A. The inability to state specific growth rates precludes a direct comparison of earnings velocity against revenue expansion, as the data points required for such an analysis are absent. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, indicating that all available earnings are retained or, in this case, that the company is retaining cash to fund operations and research. Consequently, the firm reinvests its limited financial resources entirely into growth initiatives, such as advancing its lead product candidate, rather than distributing income to shareholders. The overall growth and income profile is defined by a complete absence of current commercial earnings and dividend income, relying solely on the potential future value of its neurological disease and pain treatment pipeline.